Trump-Induced Volatility Aside, Novo Trades Cheap While Patents Protect Its Profits Until 2032
1. President Trump proposed a price cut for Novo Nordisk's drug Ozempic, causing market jitters. 2. Novo's stock trades at a low 14 P/E, showcasing strong value. 3. The company's drug patents last until 2032, ensuring market protection. 4. Novo's diverse revenue streams benefit from increased demand in obesity and diabetes treatment. 5. Despite volatility, Novo's fundamentals and growth prospects remain solid.